Cancer immunotherapy has transformed cancer treatment, with natural killer (NK) cells showing particular promise due to their ability to selectively target and eliminate cancer cells. However, effective delivery of these therapeutic cells to tumor sites while maintaining their viability remains a critical challenge. Current intravenous administration approaches suffer from rapid systemic clearance, poor tumor penetration, and off-target effects, limiting NK cell therapy effectiveness especially in solid tumors.
This ERC Proof of Concept project addressed these delivery challenges by developing an innovative biomaterial platform for controlled, localized NK cell delivery. The primary objective was creating and validating a biocompatible hydrogel system that maintains NK cell viability while providing sustained, controlled release directly at tumor sites through subcutaneous administration. The research tackled the need for improved delivery systems in solid tumor treatment, where traditional systemic approaches show limited efficacy, while addressing both clinical needs for targeted therapy and practical considerations of treatment accessibility and patient comfort.
The platform technology has potential to advance cancer immunotherapy by overcoming delivery limitations that have hindered broader clinical application of NK cell therapies. Beyond immediate therapeutic applications, this establishes a foundation for next-generation cancer treatment approaches. Clinically, the technology could enable more effective solid tumor treatment, including breast cancer subtypes with significant unmet medical needs. The controlled delivery approach may improve therapeutic outcomes while reducing systemic side effects compared to conventional cell therapy administration.
The translational potential is evidenced by industry interest and patent protection, indicating relevance to real-world clinical challenges. This interdisciplinary convergence of materials science, immunology, and clinical translation demonstrates how such approaches can address complex healthcare challenges. The work contributes to precision medicine by developing tools for targeted therapeutic delivery, potentially improving patient outcomes while advancing understanding of effective cancer treatment strategies. The completed proof-of-concept establishes a foundation for future clinical development with clear regulatory and clinical pathways identified.
